Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310.

Article  PubMed  Google Scholar 

Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:704–15.

Article  PubMed  Google Scholar 

Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, et al. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017;85:67–77.

Article  CAS  PubMed  Google Scholar 

Lulla P, Heslop HE. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematol Am Soc Hematol Educ Program. 2016;2016:390–6.

Article  Google Scholar 

Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1:2643–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma. Curr Treat Options Oncol. 2016;17:31.

Article  PubMed  PubMed Central  Google Scholar 

Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135:523–33.

Article  CAS  PubMed  Google Scholar 

Tarekegn K, Ramosa AC, Singh B, Sequeira Grossa HG, Gupta S. Checkpoint Inhibitors in relapsed/refractory classical Hodgkin lymphoma. World J Oncol. 2021;12:51–4.

Article  Google Scholar 

Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372–81.

Article  PubMed  Google Scholar 

Perdikis-Prati S, Sheikh S, Bouroumeau A, Lang N. Efficacy of immune checkpoint blockade and biomarkers of response in lymphoma: a narrative review. Biomedicines. 2023;11:1720.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16:e234–45.

Article  CAS  PubMed  Google Scholar 

Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–44.

Article  CAS  PubMed  Google Scholar 

Moore KL, Stults NL, Diaz S, Smith DF, Cummings RD, Varki A, et al. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol. 1992;118:445–56.

Article  CAS  PubMed  Google Scholar 

Guyer DA, Moore KL, Lynam EB, Schammel CMG, Rogelj S, McEver RP, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. Blood. 1996;88:2415–21.

Article  CAS  PubMed  Google Scholar 

Moore KL, Patel KD, Bruehl RE, Fugang L, Johnson DA, Lichenstein HS, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 1995;128:661–71.

Article  CAS  PubMed  Google Scholar 

Laszik Z, Jansen P, Cummings R, Tedder T, McEver R, Moore K. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood. 1996;88:3010–21.

Article  CAS  PubMed  Google Scholar 

Wilkins PP, Moore KL, McEver RP, Cummings RD. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem. 1995;270:22677–80.

Article  CAS  PubMed  Google Scholar 

Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1: A mechanism that amplifies initial leukocyte accumulation on P-selectin in vitro. J Clin Invest. 1996;98:1081–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borges E, Pendl G, Eytner R, Steegmaier M, Zöllner O, Vestweber D. The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J Biol Chem. 1997;272:28786–92.

Article  CAS  PubMed  Google Scholar 

Martinez M, Joffraud M, Giraud S, Baïsse B, Bernimoulin MP, Schapira M, et al. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J Biol Chem. 2005;280:5378–90.

Article  CAS  PubMed  Google Scholar 

Matsumoto M, Miyasaka M, Hirata T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J Immunol. 2009;183:7204–11.

Article  CAS  PubMed  Google Scholar 

Veerman KM, Carlow DA, Shanina I, Priatel JJ, Horwitz MS, Ziltener HJ. PSGL-1 regulates the migration and proliferation of CD8+ T cells under homeostatic conditions. J Immunol. 2012;188:1638–46.

Article  CAS  PubMed  Google Scholar 

McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.

Article  CAS  PubMed  Google Scholar 

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, et al. PSGL-1 Is an immune checkpoint regulator that promotes T cell exhaustion. Immunity. 2016;44:1190–203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tinoco R, Neubert EN, Stairiker CJ, Henriquez ML, Bradley LM. PSGL-1 is a T cell intrinsic inhibitor that regulates effector and memory differentiation and responses during viral infection. Front Immunol. 2021;12:677824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viramontes KM, Neubert EN, DeRogatis JM, Tinoco R. PD-1 immune checkpoint blockade and PSGL-1 inhibition synergize to reinvigorate exhausted T cells. Front Immunol. 2022;13:869768.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R. Targeting the PSGL-1 immune checkpoint promotes immunity to PD-1–resistant melanoma. Cancer Immunol Res. 2022;10:612–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kauffman K, Manfra D, Nowakowska D, Zafari M, Nguyen PA, Phennicie R, et al. PSGL-1 blockade induces classical activation of human tumor-associated macrophages. Cancer Res Commun. 2023;3:2182–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E, et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med. 1999;190:1769–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:W242–5.

Article  CAS  PubMed  PubMed Central  Google Scholar